Royal Bank of Canada’s NovoCure NVCR Stock Holding History

Royal Bank of Canada’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-192,000	Closed	-$14.4M	–	7928
2021 Q4	$14.4M	Hold	192,000	–	–	﹤0.01%	1628
2021 Q3	$22.3M	Sell	192,000 -255,800	-57%	-$38.7M	0.01%	1264
2021 Q2	$99.3M	Sell	447,800 -37,400	-8%	-$7.28M	0.03%	492
2021 Q1	$64.1M	Buy	485,200 +294,200	+154%	+$46.5M	0.02%	597
2020 Q4	$33.1M	Hold	191,000	–	–	0.01%	923
2020 Q3	$21.3M	Buy	+191,000	New	+$15.3M	0.01%	1041
2019 Q4	–	Sell	-70,000	Closed	-$5.24M	–	7028
2019 Q3	$5.24M	Sell	70,000 -20,000	-22%	-$1.6M	﹤0.01%	2040
2019 Q2	$5.69M	Sell	90,000 -115,000	-56%	-$5.83M	﹤0.01%	1973
2019 Q1	$9.88M	Buy	205,000 +11,500	+6%	+$553K	﹤0.01%	1537
2018 Q4	$6.48M	Buy	+193,500	New	+$7.08M	﹤0.01%	1796
2016 Q2	–	Sell	-30,000	Closed	-$434K	–	6470
2016 Q1	$434K	Buy	+30,000	New	+$430K	﹤0.01%	3758

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Royal Bank of Canada's NVCR Position: Q1 2026 in Review

Royal Bank of Canada reduced its NovoCure (NVCR) stake by 28% in Q1 2026, selling an estimated $45.2K and leaving 9,211 shares worth $100K. The position accounts for ﹤0.01% of the portfolio, ranked #5127.

Royal Bank of Canada first reported a position in NVCR in Q1 2016 and has held it in 40 quarters since. The position peaked at $31.9M in Q4 2020. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

Royal Bank of Canada held 9,211 shares of NovoCure worth $100K as of Q1 2026.
Royal Bank of Canada sold 3,619 NovoCure shares in Q1 2026, an estimated $45.2K.
NovoCure made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5127 holding.
Royal Bank of Canada first reported a position in NovoCure in Q1 2016 and has held it in 40 quarters since.
Royal Bank of Canada's NovoCure position peaked at $31.9M in Q4 2020.
223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.